帕博利珠单抗联合培美曲塞和铂类治疗非鳞状非小细胞肺癌:III期KEYNOTE-189研究的5年结局
III期KEYNOTE-189研究纳入616例既往未治疗、无EGFR/ALK变异的转移性非鳞状非小细胞肺癌患者,按2:1随机接受帕博利珠单抗或安慰剂联合培美曲塞和铂类。中位随访64.6个月,帕博利珠单抗组总生存风险比0.60(95%CI 0.50-0.72),无进展生存风险比0.50(95%CI 0.42-0.60),5年总生存率19.4%对11.3%。
要点
- 帕博利珠单抗联合组较安慰剂联合组降低死亡风险40%(HR 0.60,95%CI 0.50-0.72)。
- 帕博利珠单抗联合组较安慰剂联合组降低疾病进展风险50%(HR 0.50,95%CI 0.42-0.60)。
- 完成35周期帕博利珠单抗的57例患者客观缓解率86.0%,完成35周期后3年总生存率71.9%。
核心结论
- 帕博利珠单抗联合培美曲塞-铂类对比安慰剂联合培美曲塞-铂类维持了总生存和无进展生存获益,无论程序性细胞死亡配体-1表达如何。
- 这些数据继续支持帕博利珠单抗联合培美曲塞-铂类作为既往未治疗、无EGFR/ALK变异的转移性非小细胞肺癌的标准治疗。
研究设计与样本
- III期KEYNOTE-189研究(ClinicalTrials.gov标识符:NCT02578680)。
- 入组既往未治疗、无EGFR/ALK变异的转移性非鳞状非小细胞肺癌患者,按2:1随机分配至帕博利珠单抗200 mg或安慰剂每3周一次最多35周期,联合培美曲塞和研究者选择的卡铂/顺铂4周期,随后培美曲塞维持治疗直至疾病进展或不可接受的毒性。
- 共616例随机分配患者(帕博利珠单抗联合培美曲塞-铂类组n=410;安慰剂联合培美曲塞-铂类组n=206)。
- 主要终点为总生存和无进展生存。
- 随机分配至数据截止(2022年3月8日)的中位时间为64.6个月(范围60.1-72.4)。
主要发现
- 帕博利珠单抗联合培美曲塞-铂类对比安慰剂联合培美曲塞-铂类的总生存风险比为0.60(95%CI 0.50-0.72),无进展生存风险比为0.50(95%CI 0.42-0.60)。
- 5年总生存率帕博利珠单抗联合组为19.4%,安慰剂联合组为11.3%。
- 毒性可管理。
- 完成35周期帕博利珠单抗的57例患者中,客观缓解率为86.0%,完成35周期后(随机分配后约5年)3年总生存率为71.9%。
临床怎么用
- 这些数据继续支持帕博利珠单抗联合培美曲塞-铂类作为既往未治疗、无EGFR/ALK变异的转移性非小细胞肺癌的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We present 5-year outcomes from the phase 3 KEYNOTE-189 study (ClinicalTrials.gov identifier: NCT02578680). Eligible patients with previously untreated metastatic nonsquamous non-small-cell lung cancer without EGFR/ALK alterations were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles with pemetrexed and investigator's choice of carboplatin/cisplatin for four cycles, followed by maintenance pemetrexed until disease progression or unacceptable toxicity. Primary end points were overall survival (OS) and progression-free survival (PFS). Among 616 randomly assigned patients (n = 410, pembrolizumab plus pemetrexed-platinum; n = 206, placebo plus pemetrexed-platinum), median time from random assignment to data cutoff (March 8, 2022) was 64.6 (range, 60.1-72.4) months. Hazard ratio (95% CI) for OS was 0.60 (0.50 to 0.72) and PFS was 0.50 (0.42 to 0.60) for pembrolizumab plus platinum-pemetrexed versus placebo plus platinum-pemetrexed. 5-year OS rates were 19.4% versus 11.3%. Toxicity was manageable. Among 57 patients who completed 35 cycles of pembrolizumab, objective response rate was 86.0% and 3-year OS rate after completing 35 cycles (approximately 5 years after random assignment) was 71.9%. Pembrolizumab plus pemetrexed-platinum maintained OS and PFS benefits versus placebo plus pemetrexed-platinum, regardless of programmed cell death ligand-1 expression. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations.
引用
- Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023. PMID: 36809080. doi:10.1200/JCO.22.01989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。